| PCS-2023 > 3 > 3E > 3E0 > 3E04 |
3E0 | Physiological Systems and Anatomical Regions, Introduction | |
Info: | Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products | |
3E04 | Introduction, Central Vein | |
3E040 | Open | |
3E0400 | Antineoplastic | |
3E04002 | Introduction of High-dose Interleukin-2 into Central Vein, Open Approach | |
3E04003 | Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach | |
3E04005 | Introduction of Other Antineoplastic into Central Vein, Open Approach | |
3E0400M | Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach | |
3E0400P | Introduction of Clofarabine into Central Vein, Open Approach | |
3E0401 | Thrombolytic | |
3E04016 | Introduction of Recombinant Human-activated Protein C into Central Vein, Open | |
3E04017 | Introduction of Other Thrombolytic into Central Vein, Open Approach | |
3E0402 | Anti-infective | |
3E04028 | Introduction of Oxazolidinones into Central Vein, Open Approach | |
3E04029 | Introduction of Other Anti-infective into Central Vein, Open Approach | |
3E0403 | Anti-inflammatory | |
3E0403Z | Introduction of Anti-inflammatory into Central Vein, Open Approach | |
3E0404 | Serum, Toxoid and Vaccine | |
3E0404Z | Introduction of Serum, Toxoid and Vaccine into Central Vein, Open Approach | |
3E0406 | Nutritional Substance | |
3E0406Z | Introduction of Nutritional Substance into Central Vein, Open Approach | |
3E0407 | Electrolytic and Water Balance Substance | |
3E0407Z | Introduction of Electrolytic and Water Balance Substance into Central Vein, Open Approach | |
3E040F | Intracirculatory Anesthetic | |
3E040FZ | Introduction of Intracirculatory Anesthetic into Central Vein, Open Approach | |
3E040H | Radioactive Substance | |
3E040HZ | Introduction of Radioactive Substance into Central Vein, Open Approach | |
3E040K | Other Diagnostic Substance | |
3E040KZ | Introduction of Other Diagnostic Substance into Central Vein, Open Approach | |
3E040N | Analgesics, Hypnotics, Sedatives | |
3E040NZ | Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Open Approach | |
3E040P | Platelet Inhibitor | |
3E040PZ | Introduction of Platelet Inhibitor into Central Vein, Open Approach | |
3E040R | Antiarrhythmic | |
3E040RZ | Introduction of Antiarrhythmic into Central Vein, Open Approach | |
3E040T | Destructive Agent | |
3E040TZ | Introduction of Destructive Agent into Central Vein, Open Approach | |
3E040X | Vasopressor | |
3E040XZ | Introduction of Vasopressor into Central Vein, Open Approach | |
3E040G | Other Therapeutic Substance | |
3E040GC | Introduction of Other Therapeutic Substance into Central Vein, Open Approach | |
3E040GN | Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Open Approach | |
3E040V | Hormone | |
3E040VG | Introduction of Insulin into Central Vein, Open Approach | |
3E040VH | Introduction of Human B-type Natriuretic Peptide into Central Vein, Open Approach | |
3E040VJ | Introduction of Other Hormone into Central Vein, Open Approach | |
3E040W | Immunotherapeutic | |
3E040WK | Introduction of Immunostimulator into Central Vein, Open | |
3E040WL | Introduction of Immunosuppressive into Central Vein, Open | |
3E043 | Percutaneous | |
3E0430 | Antineoplastic | |
3E04302 | Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach | |
3E04303 | Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach | |
3E04305 | Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach | |
3E0430M | Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach | |
3E0430P | Introduction of Clofarabine into Central Vein, Percutaneous Approach | |
3E0431 | Thrombolytic | |
3E04316 | Introduction of Recombinant Human-activated Protein C into Central Vein, Percutaneous | |
3E04317 | Introduction of Other Thrombolytic into Central Vein, Percutaneous Approach | |
3E0432 | Anti-infective | |
3E04328 | Introduction of Oxazolidinones into Central Vein, Percutaneous Approach | |
3E04329 | Introduction of Other Anti-infective into Central Vein, Percutaneous Approach | |
3E0433 | Anti-inflammatory | |
3E0433Z | Introduction of Anti-inflammatory into Central Vein, Percutaneous Approach | |
3E0434 | Serum, Toxoid and Vaccine | |
3E0434Z | Introduction of Serum, Toxoid and Vaccine into Central Vein, Percutaneous Approach | |
3E0436 | Nutritional Substance | |
3E0436Z | Introduction of Nutritional Substance into Central Vein, Percutaneous Approach | |
3E0437 | Electrolytic and Water Balance Substance | |
3E0437Z | Introduction of Electrolytic and Water Balance Substance into Central Vein, Percutaneous Approach | |
3E043F | Intracirculatory Anesthetic | |
3E043FZ | Introduction of Intracirculatory Anesthetic into Central Vein, Percutaneous Approach | |
3E043H | Radioactive Substance | |
3E043HZ | Introduction of Radioactive Substance into Central Vein, Percutaneous Approach | |
3E043K | Other Diagnostic Substance | |
3E043KZ | Introduction of Other Diagnostic Substance into Central Vein, Percutaneous Approach | |
3E043N | Analgesics, Hypnotics, Sedatives | |
3E043NZ | Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Percutaneous Approach | |
3E043P | Platelet Inhibitor | |
3E043PZ | Introduction of Platelet Inhibitor into Central Vein, Percutaneous Approach | |
3E043R | Antiarrhythmic | |
3E043RZ | Introduction of Antiarrhythmic into Central Vein, Percutaneous Approach | |
3E043T | Destructive Agent | |
3E043TZ | Introduction of Destructive Agent into Central Vein, Percutaneous Approach | |
3E043X | Vasopressor | |
3E043XZ | Introduction of Vasopressor into Central Vein, Percutaneous Approach | |
3E043G | Other Therapeutic Substance | |
3E043GC | Introduction of Other Therapeutic Substance into Central Vein, Percutaneous Approach | |
3E043GN | Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Percutaneous Approach | |
3E043GQ | Introduction of Glucarpidase into Central Vein, Percutaneous Approach | |
3E043GR | Introduction of Other Therapeutic Monoclonal Antibody into Central Vein, Percutaneous Approach | |
3E043V | Hormone | |
3E043VG | Introduction of Insulin into Central Vein, Percutaneous Approach | |
3E043VH | Introduction of Human B-type Natriuretic Peptide into Central Vein, Percutaneous Approach | |
3E043VJ | Introduction of Other Hormone into Central Vein, Percutaneous Approach | |
3E043W | Immunotherapeutic | |
3E043WK | Introduction of Immunostimulator into Central Vein, Percutaneous | |
3E043WL | Introduction of Immunosuppressive into Central Vein, Percutaneous | |
|
ICD-10-CM-2023 Code Search Engine and PCS-2023 Code Search Engine |